Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;5(1):22-27.
doi: 10.1016/j.ajur.2017.06.001. Epub 2017 Jun 9.

Update on minimally invasive surgery and benign prostatic hyperplasia

Amanda S J Chung  1 , Henry H Woo  2
Affiliations
Review

Update on minimally invasive surgery and benign prostatic hyperplasia

Amanda S J Chung et al. Asian J Urol. 2018 Jan.

Abstract

Transurethral resection of the prostate (TURP) became the gold standard surgical treatment for benign prostatic obstruction without undergoing randomized controlled trials against the predecessor standard in open suprapubic prostatectomy. TURP has historically been associated with significant morbidity and this has fuelled the development of minimally invasive surgical treatment options. Improvements in perioperative morbidity for TURP has been creating an ever increasing standard that must be met by any new technologies that are to be compared to this gold standard. Over recent years, there has been the emergence of novel minimally invasive treatments such as the prostatic urethral lift (PUL; UroLift System), convective WAter Vapor Energy (WAVE; Rezum System), Aquablation (AQUABEAM System), Histotripsy (Vortx Rx System) and temporary implantable nitinol device (TIND). Intraprostatic injections (NX-1207, PRX-302, botulinum toxin A, ethanol) have mostly been used with limited efficacy, but may be suitable for selected patients. This review evaluates these novel minimally invasive surgical options with special reference to the literature published in the past 5 years.

Keywords: Botulinum toxin A; Ethanol; Injections; Lasers; Minimally invasive surgical procedures; Prostatectomy; Prostatic diseases; Prostatic hyperplasia; Transurethral resection of prostate.

PubMed Disclaimer

References

    1. van Rij S., Gilling P. Recent advances in treatment for benign prostatic hyperplasia. F1000Res. 2015:4. https://doi.org/10.12688/f1000research.7063.1. eCollection 2015. - DOI - PMC - PubMed
    1. Aoun F., Marcelis Q., Roumeguere T. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update. Res Rep Urol. 2015;7:125–136. - PMC - PubMed
    1. Sivarajan G., Borofsky M.S., Shah O., Lingeman J.E., Lepor H. The role of minimally invasive surgical techniques in the management of large-gland benign prostatic hypertrophy. Rev Urol. 2015;17:140–149. - PMC - PubMed
    1. Roberts W.W. New technologies in benign prostatic hyperplasia management. Curr Opin Urol. 2016;26:254–258. - PubMed
    1. Rukstalis D.B. Prostatic urethral lift: a novel approach for managing symptomatic BPH in the aging man. Can J Urol. 2015;22(Suppl. 1):67–74. - PubMed